Academicia Globe:
Inderscience Research

ISSN: 2776-1010 Volume 6, Issue 12, December 2025

BRAIN TUMOR MEDULLOBLASTOMA

Habibullo Adhamjonovich Salokhiddinov
Tashkent State Medical University, Department of Oncology,
Pediatric Oncology and Palliative Care, Assistant

Abstract
Medulloblastoma is a highly malignant primary brain tumor that originates in the cerebellum and is most commonly diagnosed in children, although it can also occur in adults. It belongs to the group of embryonal tumors and is characterized by rapid growth and a high tendency to spread through the cerebrospinal fluid. Advances in molecular biology have led to the identification of distinct molecular subgroups of medulloblastoma, which has significantly improved diagnostic accuracy and risk stratification. Early diagnosis and multimodal treatment approaches, including surgery, radiotherapy, and chemotherapy, have contributed to improved survival rates. However, treatment-related complications and long-term neurological outcomes remain major clinical challenges. This paper provides an overview of the biological characteristics, clinical presentation, and current therapeutic strategies for medulloblastoma.

Keywords: Brain tumor, Medulloblastoma, Cerebellum, Pediatric oncology, Molecular subgroups

Introduction

Brain tumors represent a significant cause of morbidity and mortality worldwide, particularly in the pediatric population. Among malignant brain tumors, medulloblastoma is one of the most common and aggressive types, accounting for a substantial proportion of childhood posterior fossa tumors. Medulloblastoma arises from primitive neuroectodermal cells in the cerebellum and typically presents with symptoms related to increased intracranial pressure, such as headaches, nausea, vomiting, and balance disturbances.Despite its aggressive nature, significant progress has been made in understanding the molecular and genetic basis of medulloblastoma. The identification of distinct molecular subgroups—such as WNT, SHH, Group 3, and Group 4—has transformed clinical management by enabling more personalized treatment strategies. Nevertheless, balancing effective tumor control with the reduction of long-term treatment-related side effects remains a critical concern. Therefore, continued research into improved diagnostic tools and targeted therapies is essential for enhancing patient outcomes and quality of life.

Medulloblastoma is a malignant embryonal tumor of the central nervous system that primarily arises in the cerebellum. It is most frequently diagnosed in children, typically between the ages of three and eight, but it can also occur in adolescents and adults. Due to its rapid growth and location in the posterior fossa, medulloblastoma often leads to early clinical manifestations, including increased intracranial pressure, hydrocephalus, and cerebellar dysfunction.Recent advances in molecular genetics have significantly improved the understanding of medulloblastoma pathogenesis. Current classification divides medulloblastoma into four major molecular subgroups: WNT-activated, SHH-

ISSN: 2776-1010 Volume 6, Issue 12, December 2025

activated, Group 3, and Group 4. Each subgroup is characterized by distinct genetic alterations, clinical behavior, and prognosis. WNT-activated medulloblastomas generally have the most favorable outcomes, while Group 3 tumors are associated with a higher risk of metastasis and poorer survival rates. This molecular stratification has become essential for guiding treatment decisions and predicting clinical outcomes.

The clinical presentation of medulloblastoma is largely determined by tumor size and its effect on cerebrospinal fluid circulation. Common symptoms include persistent headaches, morning vomiting, gait instability, and visual disturbances. In young children, irritability and developmental regression may also be observed. Diagnostic evaluation typically involves neuroimaging, with magnetic resonance imaging (MRI) serving as the gold standard for tumor detection and staging. Histopathological examination, combined with immunohistochemical and molecular analyses, is necessary to confirm the diagnosis and determine the tumor subtype.

The management of medulloblastoma requires a multimodal approach. Surgical resection is the primary treatment and aims to achieve maximal safe tumor removal. This is usually followed by craniospinal radiotherapy and systemic chemotherapy to eradicate residual tumor cells and prevent metastatic spread. Treatment intensity is adjusted based on patient age, risk classification, and molecular subgroup. In very young children, radiotherapy may be delayed or modified to reduce long-term neurocognitive side effects.Advances in treatment have led to significant improvements in overall survival rates for patients with medulloblastoma. However, long-term survivors often experience treatment-related complications, including neurocognitive impairment, endocrine dysfunction, and hearing loss. Therefore, current research focuses on developing targeted therapies and risk-adapted treatment protocols that aim to maintain high survival rates while minimizing adverse effects. Ongoing clinical trials continue to explore novel therapeutic strategies to improve both survival and quality of life for patients.

One of the defining features of medulloblastoma is its strong tendency to disseminate through the cerebrospinal fluid pathways. Metastatic spread commonly occurs along the spinal cord and leptomeninges, even at the time of initial diagnosis. For this reason, comprehensive staging, including spinal MRI and cerebrospinal fluid cytology, is essential. The presence of metastasis significantly influences risk stratification and treatment planning, often necessitating more intensive therapeutic regimens.

Histologically, medulloblastoma is not a uniform entity. Several histopathological variants have been identified, including classic, desmoplastic/nodular, extensive nodularity, and large cell/anaplastic types. These variants differ in cellular morphology, growth patterns, and clinical outcomes. For instance, desmoplastic medulloblastomas are more frequently observed in adults and are often associated with the SHH molecular subgroup. Large cell/anaplastic variants, on the other hand, are considered high-grade forms and are linked to aggressive clinical behavior and poor prognosis.

In recent years, significant efforts have been made to develop targeted therapies for medulloblastoma based on its molecular characteristics. Inhibitors targeting the SHH signaling pathway have shown promise in selected patient populations. Additionally, immunotherapeutic approaches, including

ISSN: 2776-1010 Volume 6, Issue 12, December 2025

immune checkpoint inhibitors and tumor-specific vaccines, are under investigation. Although these novel treatments are still largely experimental, they represent a potential shift toward more personalized and less toxic therapeutic strategies.The management of medulloblastoma presents distinct challenges in pediatric versus adult patients. In children, the developing brain is particularly vulnerable to the adverse effects of radiotherapy and chemotherapy, leading to long-term cognitive and developmental deficits. In adults, medulloblastoma is rarer and often diagnosed at a later stage, which may affect treatment response. These differences highlight the need for age-specific treatment protocols and long-term follow-up strategies tailored to individual patient needs.Ongoing research aims to refine risk-adapted treatment approaches by integrating molecular, clinical, and imaging data. The ultimate goal is to reduce treatment intensity for low-risk patients while intensifying or modifying therapy for high-risk cases. Advances in genomics, precision medicine, and supportive care are expected to further improve survival outcomes and enhance the quality of life for patients diagnosed with medulloblastoma.

The identification of diagnostic and prognostic biomarkers has become increasingly important in the management of medulloblastoma. Molecular profiling techniques, including gene expression analysis, DNA methylation profiling, and next-generation sequencing, allow for precise tumor classification beyond traditional histology. These biomarkers help predict treatment response, risk of recurrence, and overall prognosis. The integration of molecular diagnostics into routine clinical practice has enhanced personalized treatment planning and reduced unnecessary therapeutic toxicity in low-risk patients.

Despite therapeutic advances, treatment-related complications remain a major concern in medulloblastoma management. Craniospinal irradiation and intensive chemotherapy can lead to long-term adverse effects such as neurocognitive decline, growth retardation, endocrine abnormalities, and secondary malignancies. Hearing impairment and psychosocial challenges are also frequently reported among survivors. These complications emphasize the importance of long-term monitoring and multidisciplinary supportive care throughout survivorship.

Improving quality of life has become a central focus in medulloblastoma research and clinical care. Rehabilitation programs addressing physical, cognitive, and emotional impairments play a critical role in patient recovery. Early intervention through neuropsychological support, physical therapy, and educational assistance can significantly enhance functional outcomes. Family involvement and psychosocial counseling are essential components of comprehensive patient-centered care.Clinical trials are fundamental to advancing the understanding and treatment of medulloblastoma. Ongoing trials aim to evaluate novel therapeutic agents, optimize radiation dosing, and explore less toxic chemotherapy protocols. Participation in clinical trials provides patients access to innovative treatments and contributes to the development of evidence-based clinical guidelines. Continued international collaboration is essential for improving outcomes, particularly in rare adult cases.

Effective management of medulloblastoma requires a multidisciplinary team involving neurosurgeons, oncologists, radiologists, pathologists, rehabilitation specialists, and psychologists. This collaborative approach ensures accurate diagnosis, individualized treatment planning, and comprehensive follow-up

ISSN: 2776-1010 Volume 6, Issue 12, December 2025

care. Multidisciplinary coordination is crucial for balancing disease control with long-term well-being and functional independence.

Conclusion

Medulloblastoma remains one of the most aggressive and clinically significant malignant brain tumors, particularly in the pediatric population. Significant progress in molecular classification and diagnostic techniques has enhanced the understanding of its biological diversity and has enabled more accurate risk stratification. Multimodal treatment approaches combining surgery, radiotherapy, and chemotherapy have substantially improved survival outcomes. However, the long-term consequences of intensive therapy continue to pose major challenges, especially regarding neurocognitive function and overall quality of life.Future advances in medulloblastoma management are expected to rely on personalized, risk-adapted treatment strategies guided by molecular profiling. The development of targeted therapies and less toxic treatment protocols holds promise for reducing treatment-related morbidity while maintaining high survival rates. Continued research, multidisciplinary collaboration, and long-term follow-up are essential to further improve both clinical outcomes and life quality for patients affected by medulloblastoma.

References

1.Rutkowski S, Pfister S, Frühwald M, Fleischhack G, Korinthenberg R, Bison B, Hahn G, Mentzel H-J, Langen K-J, Hernáiz-Driever P, Pietsch T: Leitsymptome und Diagnostik der ZNS-Tumoren im Kindes- und Jugendalter. Gemeinsame Leitlinie der Gesellschaft für Neuropädiatrie und der Gesellschaft für Pädiatrische Onkologie und Hämatologie AWMF online, 2024 [URI: https://register.awmf.org/assets/ guidelines/ 025-022l_S1_Leitsymptome-Diagnostik-ZNS-Tumoren-Kinder-Jugendliche_2024-06.pdf]

2.Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW: The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology 2021 Aug 2; 23: 1231 [PMID: 34185076]

3.Erdmann F, Kaatsch P, Grabow D, Spix C: German Childhood Cancer Registry - Annual Report 2019 (1980-2018). Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz 2020 [URI: https://www.kinderkrebsregister.de/ typo3temp/ secure_downloads/ 42507/ 0/ 1c5976c2ab8af5b6b388149df7182582a4cd6a39/ Buch_DKKR_Jahresbericht_2019_komplett.pdf]

4.Fleischhack G, Rutkowski S, Pfister SM, Pietsch T, Tippelt S, Warmuth-Metz M, Bison B, van Velthoven-Wurster V, Messing-Jünger M, Kortmann RD, Timmermann B, Slavc I, Witt O, Gnekow A, Hernáiz Driever P, Kramm C, Benesch M, Frühwald MC, Hasselblatt M, Müller HL, Sörensen N, Kordes U, Calaminus G: ZNS-Tumoren. in: Niemeyer C, Eggert A (Hrsg.): Pädiatrische Hämatologie und Onkologie. Springer-Verlag GmbH Deutschland, 2. vollständig überarbeitete Auflage 2018, 359 [ISBN: 978-3-662-43685-1]

ISSN: 2776-1010 Volume 6, Issue 12, December 2025

5.Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm CM, Kuhlen M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren AO, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP: Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. American journal of medical genetics. Part A 2017, 173: 1017 [PMID: 28168833]